Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

Porcine reproductive and respiratory syndrome can cause huge economic losses to the pig breeding industry, so the market hopes to develop an effective vaccine to deal with this problem. Creative Biolabs has more than 10 years of experience in vaccine development. The established R&D platform and professional research team have ensured the reliability of our services. We also have provided a wealth of comprehensive services for a large number of vaccine researchers.

Porcine Reproductive and Respiratory Syndrome Virus

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine – Creative Biolabs

Porcine reproductive and respiratory syndrome (PRRS) is a serious disease caused by porcine reproductive and respiratory syndrome virus, the disease also known as blue-ear pig disease. This disease can affect the reproductive capacity of young pigs and cause respiratory diseases, which leads to huge economic losses every year. Therefore, it is of great significance to develop an effective vaccine against PRRS. PRRSV is a small enveloped RNA virus. The genome of the virus is a single-stranded positive-sense RNA of approximately 15 kb in size, with a total of 9 open reading frames. PRRSV has two kinds of prototype strains, VR-2332 (North American strain) and Lelystad virus (European strain), and the two strains have similar clinical symptoms, but the genome has significant differences. It is also because of the genetic variability between viruses that it is difficult to develop vaccines against them. In the early 2000s, there was a strain of HP-PRRSV of the North American genotype emerged in China that was highly pathogenic and more virulent than all other strains.

Development of Vaccine for PRRS

The first commercially available PRRS vaccine on the market is the live attenuated PRRSV vaccine- PRRSV-MLV developed more than 20 years ago. This vaccine provides homologous protection and reduces shedding of heterologous viruses, but does not provide protection against heterologous wild viruses. Despite years of research and understanding of the biology and pathogenesis of PRRSV, the vaccinology of PRRSV has not been fully understood due to the complexity of PRRSV interaction with the host and the variability of the virus. The PRRSV-MLV, a live attenuated vaccine prepared after repeated passages, has been proven to be effective and safe after many years of use and verification. Although they do not have comprehensive cross-protection. However, there are also a large number of reports that they are protective against wild isolate viruses from Asia, the United States, and Europe. The PRRSV vaccines, which use replication-capable virus as vector, are capable of eliciting cellular and humoral immune responses, and thus many viruses have been attempted to be used as vectors for the development of PRRSV. Among them, a vaccine candidate with canine adenovirus Type 2 as a vector capable of expressing PRRSV GP5 and M proteins has been reported to be able to elicit PRRSV-specific antibodies and neutralizing antibodies in the serum of mice inoculated with recombinant adenovirus. Another recombinant adenovirus expressing GP3 and GP5 of highly pathogenic PRRSV, when its target gene is fused to GM-CSF, was found to induce higher levels of PRRSV neutralizing antibodies in animals, but the recombinant adenovirus expressing only the target genes GP3 and GP5 elicited lower levels of antibodies.

In addition to the commonly used adenoviral vectors, the viral vector transmissible gastroenteritis virus (TGEV) and the bacterial vector BCG have also been developed as PRRS vaccines. Marker vaccines are also the extensively studied PRRS vaccines, and some potential marker vaccines have also been reported, but there are currently no commercially available compliance marker vaccines and paired compliance kits.

Services

  • Vaccine design and optimization
  • Vaccine analytical development & qualification
  • Vaccine preclinical assessment
  • Protein expression and purification
  • Animal models and animal assays

More than a decade of hard work in the vaccine field has made Creative Biolabs a leader in the vaccine industry. We have now established a comprehensive vaccine development system and a corresponding service system. At every step of your vaccine development, we are able to provide you with the highest quality service, allowing you to experience the most comfortable vaccine development experience. Our professional vaccine research team will be your most considerate partner, if you have any needs in this regard, please contact us immediately!


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email: Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828 Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket